Alkalinization
Analgesics..
Antiandrogens..
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Lifestyle..
Melatonin
Metformin
Molnupiravir
Monoclonals..
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Quercetin
Remdesivir
Vitamins..
Zinc

Other
Feedback
Home
Home   COVID-19 treatment studies for Zinc  COVID-19 treatment studies for Zinc  C19 studies: Zinc  Zinc   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ Mortality 65% Improvement Relative Risk c19early.org/z Elavarasi et al. Zinc for COVID-19 LATE TREATMENT Is late treatment with zinc beneficial for COVID-19? Retrospective 1,687 patients in India Lower mortality with zinc (p=0.0000016) Elavarasi et al., medRxiv, doi:10.1101/2021.08.10.21261855 Favors zinc Favors control
Clinical features, demography and predictors of outcomes of SARS-CoV-2 infection in a tertiary care hospital in India - a cohort study
Elavarasi et al., medRxiv, doi:10.1101/2021.08.10.21261855 (Preprint)
Elavarasi et al., Clinical features, demography and predictors of outcomes of SARS-CoV-2 infection in a tertiary care hospital.., medRxiv, doi:10.1101/2021.08.10.21261855 (Preprint)
Aug 2021   Source   PDF  
  Twitter
  Facebook
Share
  All Studies   Meta
Retrospective 2017 hospitalized patients in India, showing lower mortality with zinc treatment.
risk of death, 65.1% lower, RR 0.35, p < 0.001, treatment 486, control 1,201, adjusted per study, odds ratio converted to relative risk, model 4, multivariate logistic regression, control prevalence approximated with overall prevalence.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Elavarasi et al., 12 Aug 2021, retrospective, India, preprint, 26 authors.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperZincAll
Abstract: medRxiv preprint doi: https://doi.org/10.1101/2021.08.10.21261855; this version posted August 12, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission. Title page Clinical features, demography and predictors of outcomes of SARS-CoV-2 infection in a tertiary care hospital in India-A cohort study Arunmozhimaran Elavarasi1*; Hari Krishna Raju Sagiraju2*; Rohit Kumar Garg;3 Brajesh Ratre;4 Prashant Sirohiya; 4 Nishkarsh Gupta; 4 Rakesh Garg;4 Anuja Pandit;4 Saurabh Vig;4 Ram Nalwa;4 Balbir Kumar;4 Ved Prakash Meena; 3 Naveet Wig; 3 Saurabh Mittal;5Saurabh Pahuja;5 Karan Madan5; Randeep Guleria; 5 Anant Mohan; 5 Tanima Dwivedi;6Ritu Gupta;6 Ashima Jain Vidyarthi;7 Laxmitej Wundawalli;8 Angel Rajan Singh;8 Sheetal Singh; 8 Sunil Kumar;9 Sushma Bhatnagar4# *Equal contributorship 1 Department of Neurology, All India Institute of Medical Sciences, New Delhi 2 Department of Preventive Oncology, All India Institute of Medical Sciences, New Delhi 3 Department of Medicine, All India Institute of Medical Sciences, New Delhi 4 Department of Onco-anesthesia and Palliative Medicine, All India Institute of Medical Sciences, New Delhi 5 Department of Pulmonary medicine, critical care and Sleep disorders, All India Institute of Medical Sciences, New Delhi 6 Department of Laboratory Oncology, All India Institute of Medical Sciences, New Delhi 7 Department of Microbiology, All India Institute of Medical Sciences, New Delhi 8 Department of Hospital Administration, All India Institute of Medical Sciences, New Delhi 9 Department of Surgical Oncology, All India Institute of Medical Sciences, New Delhi #Corresponding Author Prof Sushma Bhatnagar Head, Department of Onco-anesthesia and Palliative care All India Institute of Medical Sciences, New Delhi sushmabhatnagar1@gmail.com Mobile:- +91-9811326453 Number of words: 3195 Number of tables: 6 Number of supplementary tables: 2 Number of references: 14 Number of figures: 2 Conflicts of interest: None of the authors report any conflict of interest Funding: No funding was obtained NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice. medRxiv preprint doi: https://doi.org/10.1101/2021.08.10.21261855; this version posted August 12, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission. Contributorship statement • • • • • • • • • • • • • Arunmozhimaran Elavarasi was involved in the conceptualization of the study, study design, patient care, data collection, statistical analysis, and in writing the first draft of the manuscript Hari Krishna Raju Sagiraju was involved in the conceptualization of the study, study design, patient care, data collection, statistical analysis, and critique of the manuscript Rohit Kumar Garg was involved in the conceptualization of the study, study design, patient care and in the critique of the manuscript Brajesh Ratre, Prashant Sirohiya, Nishkarsh Gupta, Rakesh Garg, Anuja Pandit, Saurabh Vig, Ram Nalwa, Balbir Kumar were involved in study design, patient care and in the critique of the manuscript Ved Prakash Meena was involved in the study..
Late treatment
is less effective
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit